163 related articles for article (PubMed ID: 8024753)
21. Poliovirus recombinants expressing hepatitis B virus antigens elicited a humoral immune response in susceptible mice.
Yim TJ; Tang S; Andino R
Virology; 1996 Apr; 218(1):61-70. PubMed ID: 8615042
[TBL] [Abstract][Full Text] [Related]
22. Engineering attenuated virus vaccines by controlling replication fidelity.
Vignuzzi M; Wendt E; Andino R
Nat Med; 2008 Feb; 14(2):154-61. PubMed ID: 18246077
[TBL] [Abstract][Full Text] [Related]
23. Approaches to the construction of new candidate poliovirus type 3 vaccine strains.
Almond JW; Stone D; Burke K; Skinner MA; Macadam AJ; Wood D; Ferguson M; Minor PD
Dev Biol Stand; 1993; 78():161-9; discussion 169-70. PubMed ID: 8388827
[TBL] [Abstract][Full Text] [Related]
24. Complementation of a poliovirus defective genome by a recombinant vaccinia virus which provides poliovirus P1 capsid precursor in trans.
Ansardi DC; Porter DC; Morrow CD
J Virol; 1993 Jun; 67(6):3684-90. PubMed ID: 8388519
[TBL] [Abstract][Full Text] [Related]
25. The prospective preventative HIV vaccine based on modified poliovirus.
Zhang YD; Lu XL; Li NF
Med Hypotheses; 2007; 68(6):1258-61. PubMed ID: 17196342
[TBL] [Abstract][Full Text] [Related]
26. Type 2 poliovirus recombinants isolated from vaccine-associated cases and from healthy contacts in Brazil.
Friedrich F; Da-Silva EF; Schatzmayr HG
Acta Virol; 1996 Feb; 40(1):27-33. PubMed ID: 8886095
[TBL] [Abstract][Full Text] [Related]
27. Encapsidation of genetically engineered poliovirus minireplicons which express human immunodeficiency virus type 1 Gag and Pol proteins upon infection.
Porter DC; Ansardi DC; Choi WS; Morrow CD
J Virol; 1993 Jul; 67(7):3712-9. PubMed ID: 8389902
[TBL] [Abstract][Full Text] [Related]
28. Towards development of an in vitro translation test for poliovirus neurovirulence.
Svitkin YV; Alpatova GA; Lipskaya GA; Maslova SV; Agol VI; Kew O; Meerovitch K; Sonenberg N
Dev Biol Stand; 1993; 78():27-32. PubMed ID: 8388829
[TBL] [Abstract][Full Text] [Related]
29. Complete genomic characterization of an intertypic Sabin 3/Sabin 2 capsid recombinant.
Dedepsidis E; Pliaka V; Kyriakopoulou Z; Brakoulias C; Levidiotou-Stefanou S; Pratti A; Mamuris Z; Markoulatos P
FEMS Immunol Med Microbiol; 2008 Apr; 52(3):343-51. PubMed ID: 18328076
[TBL] [Abstract][Full Text] [Related]
30. Antigenic sites of poliovirus type 3 eliciting IgA monoclonal antibodies in orally immunized mice.
Buttinelli G; Ruggeri FM; Marturano J; Novello F; Donati V; Fiore L
Virology; 2001 Mar; 281(2):265-71. PubMed ID: 11277698
[TBL] [Abstract][Full Text] [Related]
31. Poliovirus-sensitive transgenic mice as a new animal model.
Koike S; Horie H; Sato Y; Ise I; Taya C; Nomura T; Yoshioka I; Yonekawa H; Nomoto A
Dev Biol Stand; 1993; 78():101-7. PubMed ID: 8388819
[TBL] [Abstract][Full Text] [Related]
32. Poliovirus vaccine strains as mucosal vaccine vectors and their potential use to develop an AIDS vaccine.
Crotty S; Andino R
Adv Drug Deliv Rev; 2004 Apr; 56(6):835-52. PubMed ID: 15063593
[TBL] [Abstract][Full Text] [Related]
33. [Construction and identification of a vector inserted with complete genome of poliovirus strain Sabin I].
Shen HH; Hou J; Hu Y; Bai BK; Wang ZJ; Yu XH; Kong W; Liu Z; Mao PY
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2010 Feb; 24(1):59-61. PubMed ID: 20848854
[TBL] [Abstract][Full Text] [Related]
34. Minor displacements in the insertion site provoke major differences in the induction of antibody responses by chimeric parvovirus-like particles.
Rueda P; Hurtado A; del Barrio M; MartÃnez-Torrecuadrada JL; Kamstrup S; Leclerc C; Casal JI
Virology; 1999 Oct; 263(1):89-99. PubMed ID: 10544085
[TBL] [Abstract][Full Text] [Related]
35. Growth phenotypes and biosafety profiles in poliovirus-receptor transgenic mice of recombinant oncolytic polio/human rhinoviruses.
Cello J; Toyoda H; Dejesus N; Dobrikova EY; Gromeier M; Wimmer E
J Med Virol; 2008 Feb; 80(2):352-9. PubMed ID: 18098139
[TBL] [Abstract][Full Text] [Related]
36. Antigenic characterization of a formalin-inactivated poliovirus vaccine derived from live-attenuated Sabin strains.
Tano Y; Shimizu H; Martin J; Nishimura Y; Simizu B; Miyamura T
Vaccine; 2007 Oct; 25(41):7041-6. PubMed ID: 17825459
[TBL] [Abstract][Full Text] [Related]
37. Genomic modifications in Sabin vaccine strains isolated from vaccination-associated cases, healthy contacts and healthy vaccinees.
Friedrich F
Acta Virol; 1996 Jun; 40(3):157-70. PubMed ID: 8891097
[TBL] [Abstract][Full Text] [Related]
38. Chemical synthesis of poliovirus cDNA: generation of infectious virus in the absence of natural template.
Cello J; Paul AV; Wimmer E
Science; 2002 Aug; 297(5583):1016-8. PubMed ID: 12114528
[TBL] [Abstract][Full Text] [Related]
39. Strategy for construction of live picornavirus vaccines.
Nomoto A; Iizuka N; Kohara M; Arita M
Vaccine; 1988 Apr; 6(2):134-7. PubMed ID: 2838985
[TBL] [Abstract][Full Text] [Related]
40. Infectious cDNA, cell receptors and transgenic mice in the study of Sabin's poliovirus vaccines.
Racaniello VR
Biologicals; 1993 Dec; 21(4):365-9. PubMed ID: 8024752
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
